Client zone

A Novel Drug-Device Combination Product Using Terumo’s Automated Injection Device Completes Clinical Study in Japan

Aiming to Reduce the Burden on Patients Receiving Ambulatory Chemotherapy


Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo’s automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).

Kyowa Kirin initiated the clinical study in February 2020, to evaluate the safety of the product which combines the drug G-Lasta® (generic name: pegfilgrastim (genetical recombination)) and an automated injection device.

G-Lasta is a drug for decreasing incidence of febrile neutropenia in patients receiving cancer chemotherapy, launched in Japan by Kyowa Kirin in 2014. The drug is generally administered at hospitals, at least one day after chemotherapy.

This investigational product has a function to deliver G-Lasta into the patient’s body after a specified time. By applying the device on the same day of chemotherapy, it is expected to alleviate the patient’s burden of revisiting the hospital, and also reduce the workload of healthcare providers.

Terumo’s Alliance Division, a part of the General Hospital Company, is committed to developing partnerships with pharmaceutical companies. Based on Terumo’s expertise on injection needles, syringes and other core technologies related to drug administration, the company will continue to meet the expanding needs of healthcare by developing novel drug delivery systems. Moving forward, Terumo will strive to promote an even better future for healthcare together with pharmaceutical companies.



PolyNovo (ASX:PNV) infiltrates Italy’s medical device market

Medical device company PolyNovo (PNV) has entered the Italian market after appointing Medival as its distribution partner in Italy.

Italy’s medical device market is the fourth-largest in Europe, worth approximately US$10 billion (roughly A$13 billion) in value. The market demand for advanced medical products is high there, making it fertile ground for PolyNovo’s NovoSorb BTM products.

The company’s NovoSorb product range includes an assortment of bioresorbable polymers which can be produced as films, fibres, foams, and coatings. The NovoSorb BTM acts as a dermal scaffold, allowing the skin to regenerate after being burned or undergoing extensive surgery.

PolyNovo has been working with surgeons at a major hospital in the hopes of having its NovoSorb BTM product included in an important new national guideline. The hospital in question has already implanted two BTMs, with early feedback flagged as very positive.

The company’s new distribution partner, Medival, primarily provides advanced and innovative medical devices to critical care and surgical specialties. Its 25 representatives and dedicated product manager access a customer base covering approximately 1500 plastic surgeons in Italy.

PolyNovo’s Managing Director, Paul Brennan, said the company is extremely excited to enter Italy through Medival.

“The Italian market is very sophisticated, and we think it will value innovative, quality medical technologies like ours,” he said.

“The country is important both geographically and commercially, and is a major step forward in our European strategy. We will now be servicing surgeons who are a very influential throughout Europe,” he added.

This latest distribution appointment follows on from two similar appointments, which recently allowed PolyNovo to enter the Polish and Turkish markets. Back in November 2020, the company also entered the markets in Belgium, the Netherlands, Sweden, and Luxembourg.


Virtual Covid-19 wards: cutting hospital admissions with remote care

Covid-19 Virtual Wards (CVWs) are being used across the UK to relieve the intense pressure on hospitals. Medical Device Network speaks to Professor Daan Dohmen, founder and CEO of remote healthcare platform Luscii, about how CVWs are helping to reduce hospital admissions and help patients get well at home.

In the UK and across the world, hospitals have seen record admissions this winter amid the ongoing Covid-19 pandemic. Scientists feared this would happen for much of 2020, as laboratory testing found that Covid-19 was neutralised by ultraviolet sunlight but spread easily in dry, cold conditions. As skies darken and temperatures plummet, healthcare systems need to do all they can to keep the number of patients hospitalised to a minimum.

Enter Covid-19 Virtual Wards (CVWs). For hospitalised Covid-19 patients with an improving clinical trajectory, who nevertheless still need close monitoring, CVWs can allow them to head home from hospital early. This frees up their bed for a sicker patient who might need it, while allowing them to continue their recovery at home, safe in the knowledge that they’ll be promptly readmitted to hospital if things take a turn for the worse.

CVW patients are provided with a pulse oximeter and asked to take daily readings at home, alongside information about temperature and symptoms, which are uploaded into an app driven by artificial intelligence (AI). If the AI detects any abnormalities in patient data that could indicate a need for medical attention, hospital staff are notified and can take appropriate action.

Virtual wards were launched before the Covid-19 pandemic took hold, but have been of particular benefit now that the healthcare system has become so stretched.

Luscii is facilitating Covid-19 virtual wards across Europe and Africa

Remote healthcare platform Luscii is one of the tools now being used to facilitate a remote Covid-19 care.

Luscii’s CVWs are configured for the needs of each ward they are being used on, and can be rolled out within around three to five days.

Luscii founder and CEO Professor Daan Dohmen says: “In the Luscii platform there is an algorithm setting, which will detect which patients are at risk or need extra attention. An alert is automatically signalled and a nurse will then look deeper into the medical file of the patient and their data and can reach out via phone or video call, in order to do further triage and decide whether a doctor needs to be seen or an ambulance has to be sent.”

Almost 50% of hospitals in the Netherlands, where Luscii originates, use the platform for different diseases. In Europe the software is also being used in Ireland, the UK and Sweden, while in Africa it is being used in Nigeria, Kenya and Ghana.


Referral Scheme

Candidate Tools

Join our Mailing list

G2 Academy

Contact Us

We offer a national recruitment service from our Surrey head office, please see contact details below.

Head Office

PM House,
Riverway Estate
Old Portsmouth Rd

T: 01483 910 940

  • 13
  • Apr 2021

Hologic pens $795M Mobidiag buyout to expand in acute care testing

Read More

for Us

Find out More